Monday, August 15, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Nonclinical Services for Development of Interventional Agents for Infectious Diseases

by Global Biodefense Staff
April 26, 2017
NIAID Priority Pathogen Countermeasures

The National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) is seeking proposals for nonclinical product development support for promising interventional agents for infectious disease threats.

The selected contractors will assist NIAID program staff in providing all support and required documentation needed for preclinical/nonclinical activities to support Investigational New Drugs (INDs), New Drug Application (NDA), or Biologic License Applications (BLAs) for advanced products.

The development and introduction of new therapeutic products against potential agents of bioterrorism, drug-resistant pathogens, emerging and re-emerging infectious diseases, as well as infectious diseases prevalent in resource-limited countries remain a high public health priority.

To assist in filling these public health gaps, the NIAID requires a nontraditional, proactive, and product development-oriented program to provide preclinical and non-clinical development support for promising therapeutic candidates that emerge from academia, the private sector, or other sources.

SRI International was awarded a contract in 2011 to furnish such product development capabilities using the Indefinite Delivery, Indefinite Quantity (IDIQ) contract mechanism (Contract Number HHSN272201100022I). The purpose of the current solicitation is to ensure this valuable NIAID resource continues to offer a comprehensive array of capabilities with the intent of providing a discrete subset of product development services that will propel new products forward.

This resource is intended to be applied on a case-by-case basis for a diverse collection of interventional agent product candidates rather than to carry a single product candidate through the entire preclinical development pathway.

These services are intended to help a wide variety of investigators in a number of scientific areas to obtain critical data needed to attract additional funding, gain prospective partnerships (either for further development or to support clinical trials), fulfill regulatory requirements, and complete necessary studies to satisfy regulatory requirements.

This is a Multiple Award Indefinite Quantity contract with a $10,000 minimum and $94,312,400 maximum for successful performance of this contract over a period of up to 10 years.

Further details are available via Solicitation Number: RFP-NIAID-DMID-NIHAI2017090. The response deadline is Jun 28, 2017 2:00 pm Eastern.

Tags: NIAIDRequest for Proposals

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Targeting Poxviruses with Messenger RNA Technology
Medical Countermeasures

Targeting Poxviruses with Messenger RNA Technology

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC